Amicidis

Amicidis is a Canadian biotechnology company dedicated to developing a new class of anti-infective agents to combat antimicrobial resistance. The company's proprietary platform utilizes synthetic cationic polymers, known as Amicidins, which mimic the activity of natural antimicrobial peptides to rapidly neutralize a broad spectrum of pathogens. These agents are designed to be effective against multi-drug resistant bacteria and fungi while maintaining a low risk of resistance development due to their physical mechanism of action. Amicidis focuses on local applications to prevent and treat infections in high-risk settings such as surgical sites, chronic wounds, and medical device implants. By providing a versatile and stable alternative to traditional antibiotics, the company aims to address critical unmet needs in hospital-acquired infection control.